2 days Ago By ABMN Staff
CureVac ( NASDAQ:CVAC – Get Free Report ) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 3,940,000 shares, a decline of 6.4% from the November 30th total of 4,210,000 shares.
Currently, 4.2% of the shares of the stock are sold short. Based on an average daily volume of 508,300 shares, the short-interest ratio is presently 7.
8 days. CureVac Price Performance Shares of NASDAQ CVAC opened at $3.41 on Thursday.
CureVac has a twelve month low of $2.21 and a twelve month high of $5.28.
The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.
05. The firm has a 50-day moving average of $2.89 and a two-hundred day moving average of $3.
11. The company has a market capitalization of $763.43 million, a price-to-earnings ratio of 6.
20, a PEG ratio of 0.24 and a beta of 2.59.
Analysts Set New Price Targets Separately, JMP Securities restated a “market outperform” rating and issued a $16.00 target price on shares of CureVac in a research report on Monday, September 16th. Institutional Trading of CureVac Several institutional investors and hedge funds have recently added to or reduced their stakes in the business.
Private Advisor Group LLC bought a new position in shares of CureVac in the third quarter valued at $30,000. International Assets Investment Management LLC acquired a new position in shares of CureVac in the 3rd quarter worth $35,000. Integrated Wealth Concepts LLC acquired a new stake in shares of CureVac during the third quarter worth $35,000.
Bank of New York Mellon Corp acquired a new stake in shares of CureVac during the second quarter worth $54,000. Finally, Ballentine Partners LLC lifted its holdings in shares of CureVac by 58.6% during the third quarter.
Ballentine Partners LLC now owns 22,755 shares of the company’s stock valued at $67,000 after purchasing an additional 8,406 shares during the last quarter. 17.26% of the stock is owned by institutional investors and hedge funds.
About CureVac ( Get Free Report ) CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. Featured Stories Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter .
.
